Investors & Media

Webcast ImageWebcast
Leerink Partners 5th Annual Global Healthcare Conference (Live)
02/11/16 at 8:30 a.m. ET
Leerink Partners 5th Annual Global Healthcare Conference
Thursday, February 11, 2016 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Cowen and Company 36th Annual Health Care Conference  (Live)
03/09/16 at 8:00 a.m. ET
Cowen and Company 36th Annual Health Care Conference
Wednesday, March 9, 2016 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
DateTitle 
02/04/16Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 4, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 in New York, NY; Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 in Boston, MA; 28th Annual ROTH Conference on Monday, March 14, 2016 in Dana Point, CA; ... 
Printer Friendly Version
01/19/16Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Appointment adds depth in clinical and regulatory leadership CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced the appointment of Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C) as the company's Chief Medical Officer.  Dr. O'Dea will lead medical, clinical, and regulatory functions in support of volanesorsen and will al... 
Printer Friendly Version
01/13/16Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx
Ionis Earns $1.5M Milestone Payment CARLSBAD, Calif., Jan. 13, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that GSK has initiated a Phase 1 study of IONIS-HBV-LRx.  Ionis earned a $1.5 million milestone payment from GSK related to the initiation of this study.  IONIS-HBV-LRx, which was previously referred to as ISIS-GSK6-LRx, is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus (HBV).  IONIS-HBV-LRx incorporates Ionis'... 
Printer Friendly Version
01/12/16Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Ionis Earns $2.15M Milestone Payment from Biogen as Nusinersen Advances CARLSBAD, Calif., Jan. 12, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a milestone payment of $2.15 million from Biogen for completing the target enrollment of the Phase 3 CHERISH study. The study is designed to support marketing approval of nusinersen in children with spinal muscular atrophy (SMA).   "Achieving our target enrollment number in CHERISH brings us ... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
02/11/16 8:30 a.m. ET
Leerink Partners 5th Annual Global Healthcare Conference
03/09/16 8:00 a.m. ET
Cowen and Company 36th Annual Health Care Conference
03/14/16
28th Annual ROTH Conference
LocationDana Point, CA
03/15/16 2:35 p.m. ET
Barclays Global Healthcare Conference

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.